AN2 Therapeutics, Inc. Restructuring Charges
AN2 Therapeutics, Inc. (ANTX) reported Restructuring Charges of $2.23 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-03-17
- AN2 Therapeutics, Inc. restructuring charges for the quarter ending 2024-12-31 was -$9.00K.
- AN2 Therapeutics, Inc. restructuring charges for the quarter ending 2024-09-30 was $2.24M.
- AN2 Therapeutics, Inc. restructuring charges for fiscal 2024 was $2.23M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.23M derived: sum of 2 quarters · filed 2026-03-17 | $2.23M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $2.24M 10-Q · filed 2025-11-12 | $2.24M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |